Tumor necrosis factor: still a promising agent.
Frei
E
E
Dana-Farber Cancer Institute, Boston.
Spriggs
D
D
D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D006801:Humans; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha